BRAFTOVI is a kinase inhibitor that is indicated for the treatment of advanced melanoma in combination with other therapies, particularly for patients with specific BRAF mutations.

Therapeutic Effects of BRAFTOVI in the Treatment of Melanoma

BRAFTOVI (encorafenib) is an oral kinase inhibitor primarily indicated for the treatment of advanced melanoma with a BRAF V600E or V600K mutation. It is typically used in combination with binimetinib, another targeted therapy, to enhance efficacy. The drug works by inhibiting the BRAF protein, a key driver in the pathogenesis of melanoma with specific genetic mutations. This inhibition leads to the suppression of tumor growth and progression. Clinical studies have demonstrated its ability to significantly reduce tumor burden and improve progression-free survival rates in patients with metastatic melanoma. Specific dosages and combination protocols are tailored to maximize therapeutic outcomes.